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Abstract
Dengue viruses are emerging mosquito-borne pathogens belonging to Flaviviridae family which are transmitted to
humans via the bites of infected mosquitoes Aedes aegypti and Aedes albopictus. Because of the wide distribution of
these mosquito vectors, more than 2.5 billion people are approximately at risk of dengue infection. Dengue viruses cause
dengue fever and severe life-threatening illnesses as well as dengue hemorrhagic fever and dengue shock syndrome. All
four serotypes of dengue virus can cause dengue diseases, but the manifestations are nearly different depending on type
of the virus in consequent infections. Infection by any serotype creates life-long immunity against the corresponding
serotype and temporary immunity to the others. This transient immunity declines after a while (6 months to 2 years) and
is not protective against other serotypes, even may enhance the severity of a secondary heterotypic infection with a
different serotype through a phenomenon known as antibody-depended enhancement (ADE). Although, it can be one of
the possible explanations for more severe dengue diseases in individuals infected with a different serotype after primary
infection. The envelope protein (E protein) of dengue virus is responsible for a wide range of biological activities,
including binding to host cell receptors and fusion to and entry into host cells. The E protein, and especially its domain
III (EDIII), stimulates host immunity responses by inducing protective and neutralizing antibodies. Therefore, the
dengue E protein is an important antigen for vaccine development and diagnostic purposes. Here, we have provided a
comprehensive review of dengue disease, vaccine design challenges, and various approaches in dengue vaccine devel-
opment with emphasizing on newly developed envelope domain III-based dengue vaccine candidates.
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Introduction
Dengue viruses (DVs) are emerging mosquito-borne patho-
gens belonging to Flaviviridae family. They are transmitted
to humans by the bites of infected mosquitoes Aedes aegypti
andAedes albopictus. Because of the wide distribution of such
mosquito vectors, more than 2.5 billion people (two fifth of
the world’s population) approximately are at risk of dengue
infection. Dengue viruses are mostly prevalent in economical-
ly poor countries in the tropical and subtropical areas of the
world (Amitai et al. 2009; Gubler 2002). Incidence and geo-
graphical spread of dengue have greatly increased in recent
years, and it is estimated about 390 million dengue infections,
of which 96 million manifest clinically (Bhatt et al. 2013) and
22,000 deaths per year (Murrell et al. 2011). It is estimated that
3.9 billion people, in 128 countries, are at risk of dengue
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infection (Brady et al. 2012). According to the report from
BWHO^ website, a live attenuated chimeric tetravalent den-
gue vaccine, Dengvaxia® (CYD-TDV) by Sanofi Pasteur,
was recently licensed inMexico and in several other countries
including the Philippines, Brazil, El Salvador, Costa Rica,
Paraguay, Guatemala, Peru, Indonesia, Thailand, and
Singapore (http://www.sanofipasteur.com), as well.
Furthermore, five additional dengue vaccine candidates are
in clinical trial phases (Vannice et al. 2016). However, the
efforts are underway to engineer a novel tetravalent subunit
vaccine. At the present paper, we have provided a comprehen-
sive review of dengue disease, the challenges of vaccine de-
sign, and different approaches in dengue vaccine development
with emphasizing on newly developed envelope domain III-
based dengue vaccine candidates.
Dengue disease
Although first written evidence of a dengue-like disease has
been found from an old Chinese medical encyclopedia of 992,
but in recent years incidence of dengue disease has dramati-
cally increased, and now dengue infection is the most com-
mon vector-borne viral disease of humans. Dengue viruses
cause dengue disease in different levels of severity including
dengue with/without warning signs and severe dengue. Severe
dengue includes hemorrhagic fever (DHF) and dengue shock
syndrome (DSS) which both of them are severe life-
threatening illnesses. Clinical symptoms of dengue fever
(DF) are ranging from slight to mild febrile disease, which
coincides with the appearance of dengue virus in blood. DF
generally is a self-limiting disease, that the symptoms are in-
cluded severe body ache, skin rashes, and headache. In DHF
and DSS, despite the very high fever, thrombocytopenia and
hemorrhagic manifestations as well as vascular leakage into
interstitial spaces occur (Swaminathan and Khanna 2013).
Dengue viruses have four genetically different sero-
types (DV1, DV2, DV3, and DV4), which closely related
with a 65–70% nucleotide sequence homology (Rico-
Hesse 1990). All four serotypes can cause the mentioned
dengue diseases, but depending on the type of the virus in
consequent infections, the manifestations are nearly dif-
ferent (Montoya et al. 2013; Murrell et al. 2011). Infection
by any serotype creates life-long immunity against the
corresponding serotype and temporary immunity to the
others. This transient immunity declines after a while
(6 months to 2 years) and is not protective against other
serotypes (Montoya et al. 2013), even may enhance the
severity of a secondary heterotypic infection with a dif-
ferent serotype through a phenomenon known as
antibody-depended enhancement (ADE) (Halstead 2003).
Always there is chance of infection with the other three
serotypes of dengue for people who live in dengue
endemic areas, which can result in disease enhancement.
One of the possible mechanisms for this disease enhance-
ment is that the induced antibodies against the primary
infection are non-neutralizing for the secondary serotype
and can form complexes with the viruses aiding them to
entry into host cells (phagocytes and Fc receptor bearing
monocytes) via Fc receptors. This phenomenon results in
increased viral propagation and enhancement of infection
(Kliks et al. 1988). Alternatively, reactive cytotoxic T
lymphocytes against dengue antigens, with greater avidity
for the primary than the secondary serotype, may acceler-
ate the destruction of host cells and imperfect viral clear-
ance (Mongkolsapaya et al. 2003). Furthermore, it has
been shown that anti-prM/NS1 antibodies cross-react with
host endothelial antigens (Falconar 2007; Huang et al.
2006) and form complex with viruses, which target them
for entry into host cells via cross-recognition of host an-
tigens (Lin et al. 2008). On the other hand, high viral titer
triggers an intensive cytokine storm that damages the en-
dothelium and results in capillary leakage and hemorrhag-
ic manifestations (Rothman 2004).
As mentioned above, despite the potentially pathoge-
nicity of all four serotypes, there are some correlations
between dengue serotypes and the severity of infections.
For example, it has been shown that primary infection
with either serotype 1 or serotype 3 results in more sever-
ity disease than if serotypes 2 or 4 to be the primary
infection (Vaughn et al. 2000). On the other hand, it has
been found that infection by serotype 2 is associated with
severe dengue diseases (Fried et al. 2010), especially DSS
(Anantapreecha et al. 2005). Additionally, several re-
searches have shown that there is a significant correlation
between severity of secondary infections and host genetic
backgrounds (Bravo et al. 1987; Rothman 2010). A recent
study showed the impact of time intervals in severity of
dengue diseases. According to this study, longer intervals
(≥ 2.6 years) between two infections correlate with symp-
tomatic severe diseases, whereas shorter time intervals (≤
2 years) results in either protection or unapparent infec-
tion (Montoya et al. 2013). Hence, genetic background,
age, and some specific physiological conditions of indi-
viduals could be risk factors for severity of dengue dis-
eases. For instance, Caucasians, children, and individuals
affected by bronchial asthma, diabetes mellitus, and sickle
cell anemia (SCA) are more susceptible for development
of severe dengue diseases (Guzman et al. 2010).
Dengue vaccine challenges and current
approaches to develop dengue vaccines
Although the vaccines against other related flaviviruses, such
as yellow fever (YF), Japanese encephalitis (JE), and tick-
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borne encephalitis (TBE), have been developed and licensed,
efforts to develop an efficient dengue vaccine have some
drawbacks:
– The existence of four antigenically different but related
serotypes; therefore, a dengue vaccine has to be tetrava-
lent by the ability to induce balanced and stable immune
response.
– Poor understanding of biology and pathogenesis of DVs;
as the role of the immune response and the pathogenesis
of DHF/DSS are not fully understood (Halstead 1988).
While it has been explained a role for cell-mediated im-
munity in the clinical outcome of the disease, but itself
cannot play a major role in protection (Edelman and
Hombach 2008).
– The need for long-term protection; as it has been shown
that in some cases, severe dengue diseases have been
observed throughout more than 20 years after the first
infection (Alvarez et al. 2006; González et al. 2005).
– Poor understanding of the mechanism of induced protec-
tive immunity; as primary infection with any of the four
serotypes results in a lifelong immunity to that serotype,
and interim immunity to the others (Sabin 1952). On the
other hand, there is no data on the antibody titers which is
required to confer complete protection against the infec-
tion. Currently, neutralizing antibody titers are measured
using an in vitro plaque reduction neutralizing test
(PRNT), as a standard for evaluation of induced immuni-
ty. Although, the immunological relevancy of this test
should be explained (Sabin 1952; Swaminathan and
Khanna 2010). A PRNT50 titer of ≥ 1:10 is concluded
as indication for seroconversion (Delenda et al. 1994;
Guy and Almond 2008).
– Lack of a proper animal model to study the immune re-
sponse and mechanism of protection; currently, mice and
monkeys are used for this purpose but they do not man-
ifest any dengue-like diseases so that wild-type mice are
resistant to dengue-induced diseases (Murrell et al. 2011).
Although, there is no proper small animal model for eval-
uating of in vivo protective efficacy of dengue vaccines,
adult mouse models (ex. BALB/c, C3H) are often used to
assess protective level of dengue vaccines against DV2
(Apt et al. 2006;Wu et al. 2003c). However, these models
are not sensitive to DV1, DV3, and DV4. Suckling mice
which are intracranially infected with neurovirolent DV
often manifest cyrtosis, hind-leg paralysis, and death.
Therefore, suckling mice are currently a suitable model
to assess protective efficacy of dengue vaccine candidates
by observing morbidity and mortality (Mota et al. 2005).
However, the main limitation of these models is that the
mouse protection assays are focused on humoral re-
sponses as well as protective efficacy of cell-mediated
immune response is ignored. Recently, some attempts
have been performed to develop genetically engineered
mice that can develop characteristics of human dengue-
induced disease. For example, by knocking-out of inter-
feron receptors, AG129 mice showed some dengue-like
disease symptoms (Shresta et al. 2006). Also, a variety of
different mouse models such as humanized mice, chime-
ric mice transplanted with human cells, immunocompro-
mised mice, and immunocompetent mice have been de-
veloped (Balsitis et al. 2010; Clements et al. 2010;
Kuruvilla et al. 2007; Zellweger et al. 2010). The induc-
tion of viral encephalitis in immunocompetent mice has
been extensively used a model for the evaluation of the
protective capacity of vaccine candidates against lethal
challenges by dengue (Van Der Most et al. 2000). For
example, a mouse encephalitis model has been used for
evaluation of protective potential of a dengue vaccine
candidate (Marcos et al. 2013). Alternatively, it has been
reported that Asian rhesus macaques are useful animal
models for evaluation of DHF (Onlamoon et al. 2010).
However, humans are only real models of dengue dis-
eases and therefore, clinical testing and long-term assess-
ments are only means to evaluate safety, immunogenicity,
and reactogenicity of vaccine candidates (Swaminathan
and Khanna 2010). In this context, Gunther and col-
leagues have introduced Ba human challenge model^ for
dengue infection to investigate protective effects of dif-
ferent cytokines in volunteers who developed illness.
Their results revealed the critical role of IFN-γ in protec-
tion against dengue fever. The authors also suggested that
human challenge model provides an opportunity to ex-
amine efficiency of potential vaccine candidates prior to
large-scale clinical trials (Gunther et al. 2011).
– The need for vaccine trials in different geographical re-
gions to evaluate efficacy of vaccines in different epide-
miological situations (Guzman et al. 2010).
– Since the most of reported infections are from developing
countries, an ideal protective vaccine should be econom-
ically inexpensive and conferring complete protection by
just single inoculation.
In order to develop dengue vaccines, many different strat-
egies have been used (Table 1). However, each of these ap-
proaches has its unique advantages and disadvantages. For
example, live attenuated vaccines can provide long-lasting
and robust immunity but always there is a risk for reversion
to virulence forms. However, efforts of researchers over the
past six decades resulted in a live attenuated dengue vaccine
which is currently approved for human use (Dengvaxia®).
Since natural dengue infections induce solid serotype specific
immunity, live attenuated virus strains are theoretically the
most promising approach for developing an effective dengue
vaccine. But, live attenuated dengue vaccines have showed
considerable safety problems/affectivity drawbacks. On the
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other hand, non-replicating vaccines such as protein subunit
vaccines eliminate the risk of reversion but they are not potent
immunogens and need suitable adjuvants and booster immu-
nizations. Development of new approaches of chimeric mul-
tivalent vaccines and improvement of antigenicity of devel-
oped vaccine candidates in combination with new generation
of adjuvants can overcome these potential hurdles.
Virus structure and importance of envelope
protein domain III
Dengue virus particle is composed of nucleocapsid and enve-
lope. The core nucleocapsid assembles with RNA and capsid
protein (C). The viral genome is a positive-sense RNA mole-
cule by ~ 10.6 kb in length, composed of an open reading
frame (ORF). The single ORF is translated into a polyprotein
which is cleaved by both host cell and viral proteases produc-
ing three structural (capsid C, precursor membrane prM, and
envelope E) and seven nonstructural (NS1, NS2A, NS2B,
NS3, NS4A, NS4B, and NS5) proteins (Modis et al. 2003).
Despite the structural similarities, there is a variation in the
genetic sequence of different serotypes, mainly in the struc-
tural proteins that result in antigenic distinction and lack of
cross protection among the serotypes. The envelope protein E
is a large (495-amino acid residues), cysteine-rich (12 highly
conserved cysteine residues forming six S-S bonds), and mul-
tifunctional glycoprotein. The E protein is responsible for a
wide range of biological activities, including binding to host
cell receptors as well as fusion to and entry into host cells. In
addition, the E protein stimulates host immunity responses by
inducing protective and neutralizing antibodies (Henchal and
Putnak 1990; Lindenbach 2001). Therefore, the dengue E
protein is an important antigen for vaccine development and
diagnostic purposes. Immunomodulatory potential of dengue
surface protein has been evaluated by some groups (Amitai
et al. 2009; Babu et al. 2008; Fahimi et al. 2014; Kelly et al.
2000; Khanam et al. 2007; Konishi et al. 2006).
Crystallographic studies have shown that the dengue E
protein consists of three structurally distinct domains: a central
domain (EDI), a dimerization domain (EDII), and an immu-
noglobulin (Ig)-like C terminal domain (EDIII) (Modis et al.
2004, 2005) (Fig. 1). According to X-ray crystallographic
structural studies, the domain I is located in the middle of
the protein, including the N-terminal of protein with glycosyl-
ation sites. It is flanked by domain II and domain III (Modis
et al. 2003). The EDII mediates head-to-tail dimerization of E
protein and also bears the fusion loop that inserts into the
target cell membrane under the pH-dependent virus fusion.
There is a single disulfide bond (SS6) in DIII between Cys
302 and Cys 333, which is very critical for antigenic structure
of the E protein (Lin et al. 1994; Mason et al. 1990). The
folding of E protein is mainly based on beta sheet structures
and disulfide bonds. The presence of many type-specific epi-
topes in EDIII and its relatively stable conformation suggest
that it might be useful as a virus-specific antigen. It has been
Fig. 1 Crystal structural of
dimeric form of dengue envelope
protein. The most important
domain regarding to the vaccine
research in domain III. The figure
is designed based on three-
dimensional structures from PDB
site and PyMol software
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shown that individual EDIII can be independently folded as an
Ig-like structure protein (Kuhn et al. 2002) and be expressed in
the form of recombinant functional protein (Etemad et al.
2008; Guzman et al. 2010). In recent years, several groups
have shown that EDIII-based vaccine candidates can elicit
virus-neutralizing antibodies (Chen et al. 2007; Fahimi et al.
2014; Leng et al. 2009). Envelope domain III (EDIII), which
spans amino acid residues 300-400 of C-terminal of E protein,
has been composed of 10 anti-parallel beta-strands and lacks
glycosylation sites (Nayak et al. 2009; Rey et al. 1995;
Tripathi et al. 2011). This domain, which is exposed and ac-
cessible on the virion surface and is involved in host cell
surface receptor recognition, contains multiple type- and
subtype-specific conformation-dependent neutralizing epi-
topes (Kuhn et al. 2002). Neutralizing epitopes of the dengue
EDIII have been identified and included special residues 307,
333-351, and 383-389 (Modis et al. 2005). Mutations in these
sites lead to escape from neutralization by conventional mono-
clonal neutralizing antibodies (Wu et al. 2003a). This domain
appears to play a role in host cell receptor binding for viral
entry (Chin et al. 2007; Hung et al. 2004), and in inducing
long-lasting protective immunity against dengue virus infec-
tion (Muné et al. 2003; Zulueta et al. 2006). Anti-EDIII mono-
clonal antibodies are very powerful blockers of dengue infec-
tivity (Zhang et al. 2011). A study that analyzed a large panel
of anti-E monoclonal antibodies showed that those that bound
to EDIII were the most potent blockers of virus (Crill and
Roehrig 2001). In contrast, antibodies targeting either do-
mains I or II are weakly neutralizing and cross neutralize sev-
eral flaviviruses (Oliphant et al. 2006) that can lead to immune
responses developing ADE. In addition, several reports have
shown that recombinant EDIIIs can block in vitro dengue
infectivity (Hermida et al. 2006; Tripathi et al. 2008).
Importantly, EDIII has only a very low intrinsic potential for
inducing cross-reactive antibodies (Simmons et al. 1998a, b)
implicated in the pathogenesis of DHF/DSS. Choosing only
domain III as a vaccine candidate instead of whole envelope
protein has the advantage of reducing the risk of ADE because
of the absence of other non-neutralizing and cross-reactive
epitopes. There are many evidences that the most properties
of the E protein, important from a vaccine perspective, are
associated with domain III (Gil et al. 2017; Izquierdo et al.
2014; Mcburney et al. 2016; Poddar et al. 2016; Suzarte et al.
2014). Taken together, EDIII domain plays a crucial role in
dengue pathogenesis and immunity. It has also emerged as a
promising excellent vaccine candidate, so that most of recent
efforts to produce a recombinant subunit dengue vaccine have
focused on utilization of this domain.
In clinical context, it is suggested that EDIII peptides can
have considerable potential in therapeutics for dengue infec-
tion, as it has been shown that the EDIII competes with the
virus during entry by preventing viral binding to cell surface
receptors. Chin et al. have shown that recombinant EDIII1 and
EDIII2 inhibit the entry of dengue virus type 1 and 2 into host
cells (Chin et al. 2007). Another suggestion for usage of EDIII
in therapeutic approaches is the application of anti-EDIII
monoclonal antibodies to prevent the dengue diseases. As it
has been shown that anti-EDIII monoclonal antibodies are
effective blockers of dengue entry into host cells (Crill and
Roehrig 2001). It has also been reported that the murine
monoclonal antibody (mAb) 4E11, which can neutralize the
infectivity of all four serotypes, binds to EDIII (Thullier et al.
2001). On the other hand, Rajamanonmani et al. showed that
an anti-EDIII2 mouse (Amitai et al. 2009) monoclonal anti-
body cross-reacts with the EDIII (corresponding to other three
dengue serotypes) and WNV, blocking the first steps of viral
entry (Rajamanonmani et al. 2009). The authors suggested
that the viral inhibitory potential of this anti-EDIII2 antibody
and its cross-reactivity have made it a candidate for humani-
zation and therapeutic antibody-based treatment in dengue
infections.
From a different view, investigation of biological properties
of EDIII is very important in understanding on biology of
dengue virus. Pattnaik and colleagues have showed that re-
combinant EDIII4 expressed in Escherichia coli is biological-
ly functional and binds to soluble cell-free heparan sulfate
(Pattnaik et al. 2007). In addition, Wahala et al. recently have
showed that EDIII-reactive antibodies are present in primary
and secondary dengue virus immune human sera. Human an-
tibodies bound to a serotype specific epitope on EDIII after
primary infection and a serotype cross-reactive epitope on
EDIII after secondary infection. However, their results
showed that EDIII-binding antibodies constituted only a small
fraction of the total antibody in immune sera binding to den-
gue virus (Wahala et al. 2009). In another study, Li et al. have
found that majority of cross-reactive anti-EDIII mouse mAbs
do not show efficient neutralization activity (Li et al. 2013).
These authors concluded to have reconsideration on efficacy
of recombinant EDIII-based immunization strategies. Another
study indicated that anti-EDIII antibodies contribute little to
the neutralizing potency of human DENV-immune (Williams
et al. 2012). It seems that the application of only rEDIII prime-
boost immunization is not enough to induce a protective im-
mune response. Taken together, it has identified that EDIII is
the critical region for vaccine, therapeutic, and diagnosis de-
velopments, but it seems that integrative methods by using
other parts of E protein in combination with EDIII region
could be more potent approach.
EDIII-based vaccine design
As mentioned above, there are different strategies for dengue
vaccine design as well as EDIII has special advantages in
some of these strategies. A growing body of evidences, accu-
mulated in recent years, have identified that envelope domain
2982 Appl Microbiol Biotechnol (2018) 102:2977–2996
III is the critical region from the perspective of vaccine devel-
opment. Plasmids encoding EDIII and recombinant EDIII-
based fusion proteins have been shown to elicit neutralizing
antibodies in experimental animals (Chiang et al. 2013;
Guzman et al. 2010). Similarly, the capacity of recombinant
EDIII3 in the diagnosis of dengue infection and also in the
induction of neutralizing antibodies has been reported previ-
ously (Reddy et al. 2012). These findings put together justify
the choice of domain III for sub-unit vaccine development. An
overview of different EDIII-based vaccine candidates is pro-
vided below.
EDIII-based live chimeric vaccine
To encode the domain III and/or M ectodomain of dengue
virus, an EDIII-based chimeric vaccine has been produced
by the engineering of live attenuated Schwarz vaccine strain
of measles virus. Immunization by priming this chimera and
boosting with the recombinant protein were successful in in-
ducing of long-term specific neutralizing antibodies in mice.
This approach also can be used for developing of single dose
multivalent vaccines against measles virus and dengue infec-
tions, which can be very useful especially for children living
in endemic areas of both diseases such as Africa and South
America (Brandler et al. 2007; Brandler et al. 2010).
In a different approach, immunogenicity of a recombinant
Lactococcus lactis strain producing the EDIII2 by oral/nasal
administration has been shown (Sim et al. 2008). The authors
demonstrated that this mucosal vaccine candidate induces a
systemic anti-EDIII IgG antibody response in mice. They
found that the immune sera from orally inoculated mice neu-
tralize in vitro dengue infection, and also in some cases, the
neutralizing antibodies were more effective than those which
obtained with the intraperitoneally injection of inactivated
virus.
EDIII-based subunit vaccine design
In recent years, considerable research effort has been directed
towards the development of subunit dengue vaccines. Since
protein subunit vaccines employ only a portion of virus, they
are easier and safer in the production and use than live vac-
cines containing the whole genome. In terms of production
costs, subunit vaccines involve low cost in compare with
inactivated vaccines. In this field, Escherichia coli is the most
commonly used host for the production of heterologous pro-
tein (Haddad Kashani et al. 2017; Hosseini et al. 2016;
Kashani and Moniri 2015; Kashani et al. 2018). Firstly, given
the importance of recombinant EDIIIs in development of sub-
unit vaccines, we provide a review of recently reported inves-
tigations in this field.
Different approaches for expression
of recombinant EDIIIs
Important from the perspective of recombinant protein expres-
sion, the Ig-like EDIII has been shown to be a very stable and
independent folding domain (Etemad et al. 2008; Wang et al.
1999). With regard to EDIII, E. coli has served as the major
host to date (Gromowski et al. 2008; Jaiswal et al. 2004;
Saejung et al. 2006), and also there are some reports on the
use of eukaryotic systems specially Pichia pastoris (Mani
et al. 2013; Saejung et al. 2007). Some E. coli-expressed
EDIIIs tend to be insoluble and need to be purified under
denaturizing conditions, followed by renaturation (Liao and
Kielian 2005; Zhang et al. 2007). The E. coli-based systems
have the highest expression potential and cost effect scale up.
To enhance the maximum potential of this system, the
expressed protein should be moderate size (Goeddel 1990),
as well as the coding gene should be optimized and expressed
in an appropriate host. Jaiswal et al. expressed and purified
recombinant EDIII2, without any carrier in E. coli (Jaiswal
et al. 2004). Although, the N-terminal 6×-His-tagged EDIII2
protein purified during one-step purification process, but it
was overexpressed in the form of insoluble inclusion bodies.
Therefore, authors used the denaturation/renaturation strategy
for EDIII purification. However, the yield of expression and
purification was about 30 mg/L of culture and it could effec-
tively protect cells in culture against dengue virus 2 infection
by blocking the virus attachment onto host cells. Induction at
lower temperatures, periplasmic expression, and fusions to
partners or carriers such as GST, MBP, TrpE, and thioredoxin
(Saejung et al. 2006, 2007) have been employed in attempts to
increase the solubility of EDIIIs in E. coli. The main objective
of the fusion strategy has been to ensure expression in soluble
form and to provide a device for detection and purification.
Soluble expression of EDIII proteins is a key point in devel-
oping a suitable strategy for both vaccine/diagnostic purposes,
as previous studies have showed that the soluble forms of
these proteins are more effective in production of antibody
responses (Fahimi et al. 2014; Saejung et al. 2006).
Furthermore, it has been shown that some special host strains
have specific potential in soluble expression of disulfide bond
harboring proteins. Using this strategy, Jaiswal et al. have
been shown that origami strain of E. coli can be used as ap-
propriate host (Jaiswal et al. 2004). They expressed soluble
EDIII2 in E. coli using origami strain and at a low induction
temperature of 18 °C. The enhanced production of the soluble
protein attributed to the thioredoxin reductase (trxB) and glu-
tathione reductase (gor) double mutations in the origami ge-
nome. This recombinant protein was reactive with human pa-
tient antiserum and could elicit the high antigen reactive anti-
bodies in rat. In a similar way, we have showed the soluble
expression of EDIII3 protein in E. coli by using origami strain
(Fahimi et al. 2014; Prinz et al. 1997).
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In order to improve the soluble expression and immunoge-
nicity of recombinant EDIII proteins, several other different
strategies have been used. One of the most successful findings
was achieved by fusing of EDIII to P64k protein of Neisseria
meningitides. There are several reports for effective immuno-
genicity and developing potent as well as serotype specific
protective responses in immunized animal models by P64k-
EDIII fusion proteins (Hermida et al. 2004; Izquierdo et al.
2014).
Recently, considering the significant importance of EDIII
proteins in vaccine, diagnosis, and therapeutically related
fields, large-scale recombinant production of these proteins
is appeared as an interesting field in biotechnology. In this
regard, large-scale production of recombinant EDIII3 in
E. coli by using batch and fed-batch cultivation process has
recently been reported (Reddy et al. 2012; Tripathi et al.
2011). Tripathi et al. have reported the production of ~
649 mg of purified recombinant EDIII3 protein per liter of
culture. By using fed-batch cultivation and immobilized metal
affinity chromatography purification, they were able to pro-
duce recombinant EDIII protein in large scale, which can be
used for dengue diagnosis or prophylactic studies.
Furthermore, these authors have reported the large-scale pro-
duction of EDIII4 (Tripathi et al. 2008). The reported produc-
tion system resulted in overexpression of EDIII4 in the form
of inclusion bodies in E. coli, which followed by affinity chro-
matography purification with final yield of 196 mg/L of
culture.
In the field of eukaryotic expression of EDIII proteins,
Batra et al. have developed a recombinant clone of the
methylotrophic yeast Pichia pastoris capable of secreting
EDIII2. They were obtained ~ 125 mg EDIII2 with ~ 94%
purity after purification from a 10-L bioreactor (Batra et al.
2010; Etemad et al. 2008). In the context of yeasts as expres-
sion hosts, a new study has done to investigate the potential of
Saccharomyces cervisia in expression of EDIII protein.
S. cerevisiae is an attractive heterologous expression platform
that offers several advantages such as post-translational mod-
ification and secretion, as well as facility of genetic manipu-
lation and cultivation; it is also regarded as a generally recog-
nized as safe (GRAS) organism (Nguyen et al. 2013). Nguyen
et al. provided a synthetic consensus gene based on amino
acid sequences of dengue envelope domain III (scEDIII) from
all four serotypes, which the coding gene was optimized for
expression in baker’s yeast. They showed that the expressed
scEDIII was secreted into the culture media, which provides a
simple downstream purification process. The immunizedmice
with this consensus EDIII protein showed a balance immune
response against all four serotypes.
Regarding to the expression of EDIII2 in a eukaryotic host,
one of the most interesting reports is the production of EDIII2
in plant using tobacco mosaic virus-based vector system
(Saejung et al. 2007). Saejung et al. expressed EDIII2 in
Nicotiana benthamiana plant using a TMV-based transient
expression system. The expressed recombinant EDIII2 was
reactive with anti-EDIII2 polyclonal antibody and the immu-
nized mice sera neutralized dengue type-2 virus. Furthermore,
in order to achieve an edible vaccine against dengue virus,
Kim et al. expressed a consensus EDIII protein in rice (Kim
et al. 2012, 2013). These authors used a plant codon optimized
gene encoding a consensus EDIII. The results of these studies
showed the potential of transgenic rice in the expression of
two EDIII-based fusion proteins: scEDIII fused with ER re-
tention signal (scEDIII-SEKDEL) (Kim et al. 2012), and
scEDIII fused with M cell-targeting peptide ligand (scEDIII-
Co1). Altogether, the results of these studies showed the pos-
sibility of development of plant-based vaccines against den-
gue virus (Kim et al. 2012, 2013).
EDIII-based protein subunit vaccine
candidates
Antigenicity of EDIII/EDIII-fusion proteins was reported by
many investigators. Fonseca et al. showed that the recombi-
nant EDIIIs of all serotypes (expressed as fusion proteins with
the trpE tag) are antigenic. EDIII-trpE protein of each serotype
reacted strongly with hyperimmune mouse ascetic fluid
against the homologous serotype of dengue virus, with little
or without cross-reactivity (Fonseca et al. 1991). Although,
these trpE-fused recombinant proteins were not immunogenic
in mice; however, further researches in this area were very
promising. One of the earliest reports for using of domain
III-containing recombinant proteins as a dengue vaccine can-
didate was published by Srivastara et al. in 1995. They de-
signed a fusion protein containing domain III region of DV2
and a fragment containing 65 amino acids of N-terminal of
NS1 protein with staphylococcal protein A, and expressed it in
E. coli. Immunization of mice by this fusion protein (EDIII2-
NS1-protein A) resulted in induction of virus neutralizing an-
tibodies and protective immunity against intracranial lethal
challenge of mice with DV2. A very important drawback of
this vaccine candidate was high affinity of staphylococcal
protein A to human IgG, which makes it unsuitable for vacci-
nation (Srivastava et al. 1995). Another early report for using
of recombinant EDIII as a dengue vaccine candidate was pub-
lished in 1998. Simmons et al. cloned the EDIII2 coding gene
in pMAL-c2 expression vector and expressed an EDIII2-MBP
fusion protein. Immunogenicity evaluation of the purified
EDIII2-MBP protein revealed the considerable potential of
this protein in eliciting neutralizing and protective antibody
responses. Moreover, sera from immunized mice showed no
cross-neutralization activity toward any of the other dengue
serotypes (Simmons et al. 1998a, b). Expression and immu-
nogenicity of recombinant EDIII2 also have been reported by
others. Yang et al. expressed N-terminally fused EDIII2 with
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pelB bacterial secretion signal in E. coli. This protein was
immunogenic and resulted in induction of high levels of neu-
tralizing antibodies, in both BALB/c and C57BL/6 mice.
They showed that both EDIII2 and its murine antibodies pro-
tect Vero cells from DV2 infection with cross protection
against DV1 infection. Furthermore, the anti-EDIII2 antibod-
ies were able to protect suckling mice from in vivo challenge
(Yang et al. 2012). As it has been shown by Zhange et al.,
EDIII protein without any fusion tag can also be considered as
a vaccine candidate (Zhang et al. 2007). They expressed
EDIII2 in the form of inclusion bodies in E. coli, and used
multistep purification and refolding methods. This recombi-
nant protein was functional in the inhibition of plaques forma-
tion on C6/36 cells. Immunization of mice by this protein
elicited neutralizing antibodies which were protective against
viral challenge of mice.
One of the most studied EDIII-based fusion proteins
was designed by Hermida et al. (2004). They fused a frag-
ment of DV1 E protein (containing domain III) to P64K (a
meningococcal protein) and used for mice immunization.
Immunization of mice by this fusion protein elicited high
levels of neutralizing antibodies and provided significant
protection against lethal challenge with DV1. These inves-
tigators also produced a fusion protein containing dengue 2
E protein and P64K, so that immunization of mice with this
protein resulted in eliciting high neutralizing antibodies
and partially protection against lethal challenge with cor-
responding serotype of dengue virus (Hermida et al. 2004;
Izquierdo et al. 2014). Furthermore, they investigated the
immunogenicity of designed fusion protein (EDIII2-P64K)
in Macaca fascicularis monkeys. They found that this fu-
sion protein induces dengue 2 neutralizing antibodies with
protection in vaccinated nonhuman primate model
(Hermida et al. 2006).
In recent years, new strategies have been developed in the
EDIII-based protein subunit vaccine context. One of these
strategies is the production of EDIII-based chimeric fusion
proteins in combination with other proteins of dengue virus.
For instance, Marcose et al. have reported the expression,
purification, and immunogenicity of a recombinant fusion
protein (composed of EDIII2 and DV2 capsid protein of
DVs) in mice, which has resulted in eliciting neutralizing an-
tibodies (Marcos et al. 2013). Immunological evaluations re-
vealed induction of neutralizing antibodies, cell-mediated im-
munity, and protection upon virus challenge in mice.
Special advantages of EDIIIs for designing
multivalent vaccines
In the field of designing of multivalent vaccines, EDIII pro-
teins have special advantages. EDIII proteins expressed in
E. coli have extensively used for developing tetravalent
dengue vaccine candidates. For example, EDIII proteins
expressed individually and the physical mixture of all four
EDIIIs formulated as a tetravalent vaccine candidate.
Simmons et al. showed that these individual EDIIIs could
develop high titers of serotype homologous antibody re-
sponses with high virus neutralizing capacity, and also the
tetravalent formulation of four EDIII-MBP fusion proteins
was very effective in eliciting high titer of virus neutralizing
antibodies toward all four serotypes (Simmons et al. 2001).
This study revealed the potent capacity of EDIIIs in the de-
velopment of tetravalent vaccines. Although, the concerns
about carrier capacity and safety of MBP in vaccine formula-
tions should be considered.
In another report, capability of EDIII fusion in the induc-
tion of bivalent immune response has been investigated. A
chimeric bivalent antigen composing of EDIIIs of serotypes
2 and 4 was expressed in E. coli and elicited antibody re-
sponses that efficiently blocked host cell binding and neutral-
ized the infectivity of both DV 2 and DV4 (Khanam et al.
2006). Chen et al. developed a tetravalent bacterially
expressed protein composed of four EDIIIs (Chen et al.
2007). They fused the EDIIIs of all four DVs sequentially to
each other by (Gly4-Ser) 3 linkers to construct a tandem repeat
of EDIII1-2-3-4. They identified specific high antibody titers
in sera of the immunized mice against serotypes 1, 2, 4, and
moderate antibody titer against serotype 3. In challenge ex-
periment, 70% of mice challenged with serotypes 1, 2, 4 and
18% of mice challenged with serotype 3 were protected. The
results of this study suggested that the tandem repeat of
EDIIIs, forming an individual antigen, can be used as a po-
tential tetravalent dengue vaccine. However, the unbalanced
immunity that achieved in this study (weak immune response
against serotype 3) attributed to conformational problems of
tetravalent antigen. The linker that used in this study is widely
used in antibody engineering, but the authors discussed that
some special epitopes are perhaps buried inside, especially
those in EDIII3. In another report for developing tetravalent
vaccine, a tetravalent antigen has developed by providing a
consensus EDIII sequence corresponding to all four serotypes
(Leng et al. 2009). The mice immunized with this tetravalent
recombinant protein developed neutralizing antibodies against
all serotypes of dengue virus. The effectiveness of this protein
in providing protective immunity was shown by challenge
experiment on mice. The authors have suggested the possibil-
ity of developing a single tetravalent vaccine against dengue
viral infections. In a newly published study, these authors also
investigated the immunogenicity of this consensus EDIII in
non-human primates (Chen et al. 2013). The results of this
study showed the induction of immune response against all
four serotypes, although the neutralizing activity was ob-
served only for DV2. Similarly, the expression of a consensus
EDIII (cEDIII) protein in S. cervisiaewas reported by Nguyen
et al. (2013). However, the results were different between
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yeast- and E. coli-expressed cEDIIIs, in developing balanced
immune responses against different serotypes.
Another EDIII-based tetravalent antigen has been pro-
duced in Pichia pastoris, which elicits neutralizing antibodies
against all four dengue serotypes. Etemad et al. developed a
tetravalent chimeric protein by fusing the EDIII of the four
serotypes together, using pentaglycine peptide linkers. The
designed tetravalent antigen (tandem EDIII1-2-3-4) induced
neutralizing antibodies toward all four serotypes (Etemad
et al. 2008). This study showed the promising potential of
EDIII in developing a tetravalent dengue vaccine using
Pichia pastoris system.
In addition to the mentioned yeast systems, in order to
develop EDIII-based subunit vaccines, the capability of insect
cell-based systems has also been investigated. As recently
reported, Block et al. have expressed all four EDIIIs (1–4) in
the insect cells (Block et al. 2010). The secreted EDIIIs used
for mice immunization individually and also in a tetravalent
formulation (physical mixture of four EDIIIs), which resulted
in eliciting serotype specific neutralizing antibody responses.
Interestingly the tetravalent formulation elicited neutralizing
antibodies toward all four serotypes. To achieve balance
among serotype specific neutralizing antibodies, the authors
suggested dose adjustment in relative amount of each EDIII
protein in tetravalent formulation.
Before the application of EDIII-based strategies, most of
the efforts to develop a dengue vaccine have been based on
development of monovalent (single serotype-specific) vac-
cines. Adjusting of balanced vaccine dose in tetravalent for-
mulation of monovalent mixtures is a big problem.When four
monovalent vaccines were mixed together into a single tetra-
valent formulation, immune responses were predominantly
directed to one serotype with the exclusion of the others
(Swaminathan and Khanna 2010). The induction of unequal
levels of neutralizing antibodies against the all four serotypes
can cause vaccine-induced severe dengue illnesses. EDIII-
derived tetravalent fusion proteins can eliminate this problem.
Taking into account the special advantages mentioned above,
EDIII-based proteins have special advantages for developing
of tetravalent vaccine candidates. These benefits have led to
an increase in the number of reports of tetravalent dengue
vaccines development by using EDIII-based recombinant/
chimeric proteins (Block et al. 2010; Brandler et al. 2010;
Chiang et al. 2016a, b; Izquierdo et al. 2014; Valdés et al.
2017). In this way, Bioinformatics has also been able to accel-
erate the design of tetravalent vaccines by using in silico
methods (Fahimi et al. 2016). EDIII-based tetravalent vaccine
candidates are developed in different vaccine platforms. For
instance, chimeric proteins and DNA/viral vectored vaccines
have developed by fusing the domain III of four serotypes
(Table 2). Immunization experiments with these chimeric
EDIIIs resulted in induction of neutralizing antibodies toward
all four serotypes.
EDIII-based DNA and viral vectored vaccines
The DNA and vectored vaccines provide in vivo expression of
target antigens. In this context, several studies have showed
effectiveness of EDIII-based approaches. For instance, an
EDIII-based DNA vaccine was developed by physically
mixing of four individual pcDNA3 vectors containing
EDIII-coding genes of four serotypes (Mota et al. 2005).
Mice immunized with either individual DIII constructs or
the tetravalent formulation developed antibodies against each
corresponding dengue serotype. Individual EDIII plasmid/
tetravalent formulations showed the neutralizing titers of
1:10 against DV2. Forty-three percent of newborn mice chal-
lengedwith DV2 in combination with anti-EDIII2 serumwere
protected, whereas the tetravalent antiserum protected 87% of
challenged mice. In this study, evaluation of possible DNA
vaccine-induced cellular immune responses revealed no de-
tectable virus-induced cell proliferation responses in immu-
nized mice. The authors suggested that cellular responses in-
duced by the EDIII plasmids are not stronger and to be detect-
ed in proliferation assays, in agreement with results reported
by Konishi et al. (2000). In another report Ramanathan et al.
developed a human codon optimized tetravalent DNAvaccine
by fusing the all four consensus EDIII coding sequences to-
gether and the construction of a single ORF in a mammalian
expression vector. The designed SynConTM DNAvaccine re-
sulted in tetravalent protective immunity against all four den-
gue serotypes in mice. In order to separation of domains (to
achieve proper protein folding) and providing proteolytic
cleavage sites (for better CTL processing), they used amino
acid sequence of RGRKRRS as linker between EDIII of dif-
ferent serotypes. The elicited tetravalent antibodies neutral-
ized all dengue serotypes and prevented cell death induced
by dengue infection (Ramanathan et al. 2009).
Khanam et al. used an adenoviral/plasmid vector express-
ing tandem EDIII2-4 dimer for immunization of mice. The
immunization resulted in the induction of antibodies that spe-
cially bound to and neutralized the infectivity of DV2 and 4
but not DV1 and 3. Furthermore, analysis of cell-mediated
immunity using in vitro re-stimulation of splenocytes from
immunized mice showed a significant proliferation response
accompanied by the production of high levels of cytokines
(INFγ and IL-4) (Khanam et al. 2007). Another viral vectored
dengue vaccine candidate was developed by using an adeno-
virus type 5 (AdV5) vector encoding an EDIII-based tetrava-
lent antigen which was able to elicit immune responses against
all four dengue serotypes. The expressing vector was con-
structed by in-frame fusion of the four EDIII-coding se-
quences and used for mice immunization. This rAdV5 vector
induced cell-mediated immune responses and virus neutraliz-
ing antibodies specific to the all four DVs. The interesting
finding of this work was that anti-AdV5 antibodies in the
hyper immune sera could promote uptake of a rAdV5-
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derived reporter vector into U937 cells. Authors suggested
that pre-existing immunity to AdV5 may facilitate the uptake
of rAdV5 vectored vaccines into antigen presenting cells and
thus promote the induction of a robust antigen-specific im-
mune response (Khanam et al. 2009). Novel EDIII-based
DNA vaccines by using different strategies for immunization
(DNA vaccine alone/in combination with recombinant pro-
teins) have been recently developed (Blair et al. 2006; Lima
et al. 2011; Mcburney et al. 2016; Raviprakash et al. 2006).
Most of recently developed DNA vaccines resulted in induc-
tion of tetravalent immunity and neutralizing antibodies
against all four serotypes.
Strategies for enhancing the immunogenicity
of EDIII proteins
One of the common drawbacks of subunit protein vaccines is
low immunogenicity of these antigens. In order to enhance the
immunogenicity of EDIII proteins, different traditional adju-
vants (e.g., Freund’s adjuvant/aluminum hydroxide) and new
approaches (CpG repeated DNA sequences, liposomes, and
fusion tags) have been used. However, because of possible
induction of strong hypersensitivity responses by complete
FA, it cannot be accepted as a human vaccine component.
Also safety of CpG’s for human use is not clearly known
yet. As an interesting alternative, liposomes are known to be
safe for human use. It has reported that EDIII-based peptides
could be linked to cationic liposomes as an adjuvant (Chávez
et al. 2010; Wu et al. 2003b).
Combination of EDIII proteins with adjuvants is a useful
approach to improve the immunogenicity of these proteins. In
a study, Bernardo et al. investigated the effectiveness of two
Freund’s and aluminum hydroxide adjuvants on immunoge-
nicity of a recombinant fusion protein (containing EDIII1 and
P64K protein from Neisseria meningitides) in non-human pri-
mates (Bernardo et al. 2008). They found that vaccination by
Freund’s adjuvant is more immunogenic than aluminum hy-
droxide. Following challenge with DV1, animals which im-
munized by using Freund’s adjuvant were protected from vi-
remia, whereas monkeys receiving antigen in aluminum hy-
droxide developed a poor antibody response and were not
protected from viral challenge. In another study, to enhance
the immunogenicity of EDIII2-p64K fusion protein, a capsu-
lar polysaccharide from N. meningitides serogroup A (CPS-
A), which was adsorbed on aluminum hydroxide, has been
used as an effective vaccine adjuvant (Valdés et al. 2009).
Babu et al. investigated the immunogenicity of a bacterially
expressed EDIII4 with various adjuvants in mice (Babu et al.
2008). They showed that although EDIII4-immunized mice
develop neutralizing antibody titer, but EDIII4 in combination
with montanid and Freund’s complete adjuvants gives highest
antibody titers (1:128).Ta
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In addition to using adjuvants, application of fusion protein
strategy is another different and interesting strategy to im-
prove the immunogenicity of EDIII. For example, fusion of
EDIII and bacterial A protein (Srivastava et al. 1995), MBP
protein (Simmons et al. 1998a, b), lipoproteins (Chen et al.
2009), and P64K protein (Izquierdo et al. 2014; Valdés et al.
2009), have been reported previously. Lazo et al. designed a
fusion protein from EDIII4 and meningococcal P64k protein
carrier, by inserting two EDIII4 fragments in both sites of
P64k. After immunization of mice with this fusion protein,
despite the induction of low levels of antiviral antibodies,
significant protection was observed against viral challenge
with DV4 (Lazo et al. 2009). Furthermore, it has been shown
that incorporation of the dengue capsid protein beside the
EDIII can further induce cell-mediate immunity (Suzarte
et al. 2014, 2015). The EDIII-based heterodimers are the other
strategy in the development of fusion proteins to enhance the
immunogenicity. In this field, Chiang et al. have reported a
novel approach (Chiang et al. 2013). They expressed a recom-
binant lapidated EDIII1 (LD1EDIII) in an E. coli system. This
new lipoprotein that contains a bacterial lipid moiety, as a
po t en t immunomodu l a to r , showed an inhe r en t
immunostimulation effect with activating macrophage cells.
Whereas, its non-lipidated form (EDIII1) did not show similar
effect. They also showed that LD1EDIII in combination with
a multiphase emulsion system increased the antigen associa-
tionmore effective way than antigen alone. In fact, application
of newly developed water-in-oil-in-water multiphase emul-
sion system (termed PELC) is one of the recent approaches
to enhance the immunogenicity of EDIII proteins. Efficiency
of PELC in potentiating the protective capacity of EDIII1 has
recently reported (Chiang et al. 2012). Unlike aluminum phos-
phate , EDIII1 formula ted with PELC plus CpG
oligodeoxynucleotides induced neutralizing antibodies
against DV1 and increased the INFγ secretion by splenocytes
after in vitro re-stimulation (Chiang et al. 2012, 2013).
EDIII2-HBcAg is another heterodimeric fusion protein that
has been developed by Arora et al. (2012). They showed that
bacterially expressed EDIII2 in fusion with Hepatitis B virus
core antigen (HBcAg) assembles into 35–40 nm VLPs. The
produced VLPs were highly immunogenic in eliciting high
titer antibodies which were able to bind and neutralized
DV2. The authors suggested that EDIII-displaying nanoparti-
cles may have potential applications in diagnostic/vaccine for
dengue.
As mentioned above, Brandler et al. have used live attenu-
ated Schwarz measles vaccine (MV) as a vector containing
EDIII1 coding gene which fused to the ectodomain of the
membrane protein from dengue type 1 (EDIII1-ectoM).
They showed that the presence of ectoM is critical to the
immunogenicity of inserted EDIII1. The remarkable adjuvant
capacity of ectoM in immunogenicity of EDIII was correlated
with its ability to promote the maturation of dendritic cells and
the secretion of a panel of antiviral cytokines and chemokines
involved in adaptive immunity (Brandler et al. 2007).
In the context of fusion of EDIIIs to lipoproteins, Chen
et al. showed the effectiveness of Ag473 lipoprotein of
N. meningitidis. According to this study, the EDIII-Ag473
fusion conferred induction of higher levels of neutralizing
antibodies than EDIII alone or formulated in alum (Chen
et al. 2009). Investigation on the mechanism of this enhance-
ment revealed that EDIII-Ag473 activates antigen presenting
cells (APCs) as an intrinsic adjuvant. The authors discussed
that the adjuvant activity appears to be due to stimulation of
innate immunity through the TLR2 signaling pathway, trig-
gered by recombinant EDIII-lipoprotein (Leng et al. 2010).
Another alternative method to enhance immunogenicity of
EDIII is to target the antigen to dendritic cells in order to induce
T cells for broad antibody responses. Coconi-Linares et al.
fused EDIII2 to a single chain antibody fragment (scFv), which
was raised against the DEC-205 receptor. This recombinant
fusion protein was expressed in Nicotiana benthamiana and
used for mice immunization, which resulted in specific and
strong humoral responses with anti-dengue neutralizing anti-
bodies (Coconi-Linares et al. 2013). The main point in this
approach was that only two immunizations were required to
generate a memory response without the presence of adjuvants.
Oligonucleotides are also new adjuvants that can be used in
either protein- or DNA-based approaches. The effectiveness
of DNA oligonucleotides in induction of immune system has
been previously reported. Marcos et al. showed the ability of
the viral capsid/EDIII proteins in combination with DNA ol-
igonucleotides (ODN) in producing nucleocapsid-like parti-
cles (NLPs) (Marcos et al. 2013). Several studies indicated
the adjuvant capacity of ODNs in the induction of cell-
mediated immunity against the target antigens (Gil et al.
2015; Vollmer 2006). The adjuvant capacity of NLPs was also
reported by Lazo et al., where they reported that immunization
of mice with a formulation containing NLPs of DV2 with
chimeric EDIII4-P64k protein results in high levels of antivi-
ral antibodies (Lazo et al. 2010). As a different strategy, the
application of other carrier proteins with immune-stimulatory
properties such as cholera toxin B subunit (CTB) has been
suggested (Kim et al. 2016). Furthermore, in DNA vaccine
context, granulocyte-macrophage colony-stimulating factor
(GM-CSF) gene is one of the most attractive adjuvants
(Zheng et al. 2011).
In addition to the mentioned strategies to improve the im-
munogenicity of dengue EDIII-based antigens, there are some
other strategies that have been used for enhancement of anti-
genicity of other non-dengue flaviviral EDIIIs. Similarly, we
suggest these strategies in the case of dengue vaccine research.
For instance, a subunit vaccine against West Nile Virus
(WNV) has been developed by fusing the EDIII of the
WNV to STF2Delta. STF2Delta is a modified version of bac-
terial flagellin that has been used as an adjuvant (Huleatt et al.
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2007). Immunization of mice with this fusion protein (without
any routine adjuvant) elicited strong anti-WNV antibody re-
sponse that neutralized viral infectivity and conferred protec-
tion against viral challenge. In another strategy by Spohn
et al., a WNV vaccine candidate developed by chemically
coupling of a recombinant EDIII to viral like particles
(VLPs). Unlike the individual EDIII of WNV, which required
three immunizations to achieve antibody response, a strong
immune response was achieved after just a single injection
of EDIII-VLPs. The induced antibodies were able to neutral-
ize the virus in vitro and provide protection against viral chal-
lenge (Spohn et al. 2010).
Although there is a growing evidence of effectiveness of
EDIII-based strategies in induction of protective immunity in
animal models, some studies have provided special consider-
ations about application of EDIII-based strategies for human
vaccine development. As showed by Wahala et al., EDIII-
binding antibodies make just a small number of the total anti-
body in human immune sera binding to DVs. According to
their study, EDIII-binding antibodies in human sera play a
minor role in virus neutralization (Wahala et al. 2009). In this
context, some studies suggested the heterologous prime-boost
strategy using EDIII proteins to direct immune system to spe-
cific neutralizing antibodies on EDIII protein. Recent studies
done by Zlatkovic et al. revealed the low potency of WNV
EDIII for priming, but excellent boosting effect was shown for
this protein. They suggested a new heterologous prime-boost
vaccination strategy, which primes by inactive virus/complete
E protein and is followed by using EDIII as a booster antigen
(Zlatkovic et al. 2011). Valdes et al. have used a similar het-
erologous prime-boost strategy by prime immunization of
monkeys with inactive DV2 and boosting by a recombinant
EDIII-Capsid fusion protein. They found that animals devel-
oped a neutralizing antibody response following primary vac-
cination and the immune response significantly boosted after
the second immunization by recombinant EDIII (Valdés et al.
2011). The authors concluded that EDIII protein as a perfect
booster antigen is able to recall the neutralizing antibody re-
sponse elicited following viral infection in monkeys. Hence, it
is suggested to be considered the booster effect of rEDIIIs in
future vaccine strategies.
Conclusion and future perspectives
Recently, because of the spread of the mosquito vectors and
worldwide trips, the occurrence of dengue infection has alarm-
ingly increased. The vaccination could provide a promising
approach for controlling dengue virus infections. Several re-
search groups worldwide are exploring different approaches
towards developing dengue vaccine on the basis of conven-
tional live attenuated viruses, inactivated viruses, infectious
clone-derived attenuated viruses, DNA/viral vaccines, and
recombinant dengue viral proteins expressed in heterologous
systems (Tables 1 and 2). Each approach of dengue vaccine
development has its own advantages and disadvantages.
Protein subunit vaccines offer several advantages over other
approaches such as follows:
– No biohazard problem because of the lack of a replicating
virus (which is a major problem in live attenuated and
inactivated vaccines.)
– Easy to produce and scale up and can be inexpensive
– Special ability to induce a balanced tetravalent immune
response compared to four replicating viruses (in the con-
text of a tetravalent formulation) (Swaminathan and
Khanna 2010).
Therefore, the recombinant subunit vaccines may provide
an attractive alternative to live attenuated/killed vaccines.
Dengue virus envelope protein (E protein) is the most
attractive viral protein in both vaccine and diagnostic pur-
poses. Many attempts have been made to produce a re-
combinant dengue E protein in a heterologous expression
system including Escherichia coli, yeast, insect, and plant
(Table 2). Most of attempts for production of E protein in
E. coli result in formation of an insoluble protein or an
inclusion body, which further requires subsequent compli-
cated and time-consuming denaturation/refolding for pro-
tein purification. As large proteins such as E protein tend
to be expressed at lower levels, the recent attempts direct-
ed to the expressing a small and biologically critical do-
main (domain III) of the E protein in E. coli. Furthermore,
chimeric proteins containing domain III have been dem-
onstrated to be immunogenic, capable of inducing neutral-
izing antibodies in experimental animals. The most impor-
tant benefit of EDIII-base vaccine is although EDIII rep-
resents only a fraction of the envelope protein, the remov-
al of other epitopes that elicit non-neutralizing, cross-
reactive antibodies should reduce the risk of disease pro-
gression to DHF or DSS. It is appear that a safe and
effective vaccine must target neutralizing antibody re-
sponses away from less accessible and weakly neutraliz-
ing, to freely accessible and strongly neutralizing epitopes
(Apt et al. 2006). Even though EDIII presents only a
fraction the E protein, the absence of other epitopes which
elicit non-neutralizing, cross-reactive antibodies could
have advantages in reducing risk for developing ADE.
In this context, the EDIII of the E protein has emerged
as a very promising vaccine candidate in recent years. It is
very important presenting antigens from all serotypes in a
manner to elicit immune responses in equal proportion.
Whenever a dengue vaccine does not provide protection
against all four serotypes, a vaccinated individual will be
susceptible to development of a more severe disease
(DHF/DSS) if infected by untargeted serotypes. One
2990 Appl Microbiol Biotechnol (2018) 102:2977–2996
approach that has been suggested to minimize the possi-
bility of antibody-dependent infection enhancement oc-
curring after vaccination is to design a tetravalent subunit
dengue vaccine. This type of vaccine contains epitopes
inducing high levels of specific neutralizing antibody to
all four serotypes, but contains a minimum of dengue
complex cross-reactive epitopes which are presumably re-
sponsible for the induction of enhancing antibodies
(Simmons et al. 1998a, b).
To achieve equal expression of antigens from all four sero-
types, it should design the EDIII antigens of the four serotypes
of virus as an individual protein. However, the detailed mech-
anism of dengue infection and also vaccine provided protec-
tion are not clearly explained, up to now. In addition, for
designing a dengue vaccine which is protective against all four
serotypes, without any potential risk of disease severity en-
hancement, the molecular mechanism of dengue pathogenesis
must be considered (Miller 2010; Murrell et al. 2011). It is
expected that in the coming years more data on dengue path-
ogenesis and protection mechanisms will be available. The
new data from Phase III clinical trials of current dengue
LAVs/chimeric vaccine candidates and also more evaluations
of newly developed EDIII-based vaccines will help us to have
a better knowledge about the mechanism of protection.
In conclusion, dengue vaccine researches especially in the
field of tetravalent vaccines have increased in the last years
and evaluation of these recent efforts shows that dengue do-
main III is the basic substance in the most of the reported
studies. Now, construction of tandem repeats of consensus
EDIIIs (tetravalent EDIII-based antigens) which elicit neutral-
izing antibodies against the all four serotypes of dengue virus
is the broadly accepted approach for development of a desired
vaccine. Reviewing of the findings from the recent studies has
showed the effectiveness of EDIII-based approaches in tetra-
valent dengue vaccine design. On the other hand, new ap-
proaches by using DNA shuffling, bioinformatics, and
immunoinformatics methods have enhanced the vaccine de-
sign progress (Fahimi et al. 2016; Sánchez-Burgos et al.
2010). Many promising researches have been published in
the field of rational design of vaccines against dengue virus,
which the most cases have been performed on the base of
dengue virus E protein domain III. Despite the advent of first
licensed dengue vaccine (Dengvaxia®), there are many uni-
versities, research centers, and companies which are being
competition to achieve a safer and effective dengue vaccine.
It seems that the current promising researches on dengue vac-
cines will lead us to achieve a desirable human vaccine in the
near future.
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